| 3.935 -0.115 (-2.84%) | 10-02 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |   |
|||
| Targets | 6-month : | 8.76 | 1-year : | 10.23 |
| Resists | First : | 7.5 | Second : | 8.76 |
| Pivot price | 6.09 |
|||
| Supports | First : | 3.06 | Second : | 0.33 |
| MAs | MA(5) : | 4.47 |
MA(20) : | 4.67 |
| MA(100) : | 1.44 |
MA(250) : | 1.13 |
|
| MACD | MACD : | 0.8 |
Signal : | 1.2 |
| %K %D | K(14,3) : | 37.9 |
D(3) : | 52.3 |
| RSI | RSI(14): 49.7 |
|||
| 52-week | High : | 7.5 | Low : | 0.25 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ NRSN ] has closed above bottom band by 6.6%. Bollinger Bands are 183.9% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 14 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 4.04 - 4.07 | 4.07 - 4.1 |
| Low: | 3.74 - 3.79 | 3.79 - 3.82 |
| Close: | 3.94 - 4.02 | 4.02 - 4.08 |
NeuroSense Therapeutics Ltd. operates as a biotechnology firm in the clinical development phase, committed to discovering and developing effective therapies for individuals suffering from severe neurodegenerative conditions. The company's leading drug candidate, PrimeC, is an innovative oral formulation that has successfully concluded Phase IIa clinical investigations for the management of amyotrophic lateral sclerosis (ALS). Additionally, its early-stage research pipeline features StabiliC, a potential treatment for Parkinson's disease, and CogniC, which is under development for Alzheimer's disease. Established in 2017, NeuroSense Therapeutics Ltd. is headquartered in Herzliya, Israel.
Fri, 02 Oct 2026
Neurosense Therapeutics Stock Price Forecast. Should You Buy NRSN? - StockInvest.us
Fri, 02 Oct 2026
The $1 bid-price hurdle is cleared, but NeuroSense (Nasdaq: NRSN) still faces delisting. - stocktitan.net
Fri, 02 Oct 2026
NeuroSense Provides Update on Nasdaq Listing Compliance - PR Newswire
Wed, 30 Sep 2026
NeuroSense Therapeutics (Nasdaq:NRSN) - Stock Analysis - Simply Wall Street
Mon, 28 Sep 2026
NeuroSense CFO will meet investors one-on-one in New York - stocktitan.net
Fri, 25 Sep 2026
NeuroSense Provides Business Update and Progress for the First Half of 2026 - PR Newswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 38 (M) |
| Held by Insiders | 2.387e+007 (%) |
| Held by Institutions | 25.6 (%) |
| Shares Short | 548 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.107e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -247.4 % |
| Return on Equity (ttm) | -2 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 110.74 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -0.5 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -8 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0.03 |
| Price to Cash Flow | -126.41 |
| Dividend | 0 |
| Forward Dividend | 489130 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|